Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 148

Cited In for PubMed (Select 17700700)

1.

Targeting cell cycle regulators in hematologic malignancies.

Aleem E, Arceci RJ.

Front Cell Dev Biol. 2015 Apr 9;3:16. doi: 10.3389/fcell.2015.00016. eCollection 2015. Review.

2.

CDK1 structures reveal conserved and unique features of the essential cell cycle CDK.

Brown NR, Korolchuk S, Martin MP, Stanley WA, Moukhametzianov R, Noble ME, Endicott JA.

Nat Commun. 2015 Apr 13;6:6769. doi: 10.1038/ncomms7769.

PMID:
25864384
3.

CDK1 inhibition targets the p53-NOXA-MCL1 axis, selectively kills embryonic stem cells, and prevents teratoma formation.

Huskey NE, Guo T, Evason KJ, Momcilovic O, Pardo D, Creasman KJ, Judson RL, Blelloch R, Oakes SA, Hebrok M, Goga A.

Stem Cell Reports. 2015 Mar 10;4(3):374-89. doi: 10.1016/j.stemcr.2015.01.019. Epub 2015 Feb 26.

4.

Lhx4 deficiency: increased cyclin-dependent kinase inhibitor expression and pituitary hypoplasia.

Gergics P, Brinkmeier ML, Camper SA.

Mol Endocrinol. 2015 Apr;29(4):597-612. doi: 10.1210/me.2014-1380. Epub 2015 Feb 10.

PMID:
25668206
5.

Cell cycle control by a minimal Cdk network.

Gérard C, Tyson JJ, Coudreuse D, Novák B.

PLoS Comput Biol. 2015 Feb 6;11(2):e1004056. doi: 10.1371/journal.pcbi.1004056. eCollection 2015 Feb.

6.

Tudor staphylococcal nuclease (Tudor-SN), a novel regulator facilitating G1/S phase transition, acting as a co-activator of E2F-1 in cell cycle regulation.

Su C, Zhang C, Tecle A, Fu X, He J, Song J, Zhang W, Sun X, Ren Y, Silvennoinen O, Yao Z, Yang X, Wei M, Yang J.

J Biol Chem. 2015 Mar 13;290(11):7208-20. doi: 10.1074/jbc.M114.625046. Epub 2015 Jan 27.

PMID:
25627688
7.

Targeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitors.

Peyressatre M, Prével C, Pellerano M, Morris MC.

Cancers (Basel). 2015 Jan 23;7(1):179-237. doi: 10.3390/cancers7010179. Review.

8.

Hematopoiesis specific loss of Cdk2 and Cdk4 results in increased erythrocyte size and delayed platelet recovery following stress.

Jayapal SR, Wang CQ, Bisteau X, Caldez MJ, Lim S, Tergaonkar V, Osato M, Kaldis P.

Haematologica. 2015 Apr;100(4):431-8. doi: 10.3324/haematol.2014.106468. Epub 2015 Jan 23.

9.

The FBXL10/KDM2B scaffolding protein associates with novel polycomb repressive complex-1 to regulate adipogenesis.

Inagaki T, Iwasaki S, Matsumura Y, Kawamura T, Tanaka T, Abe Y, Yamasaki A, Tsurutani Y, Yoshida A, Chikaoka Y, Nakamura K, Magoori K, Nakaki R, Osborne TF, Fukami K, Aburatani H, Kodama T, Sakai J.

J Biol Chem. 2015 Feb 13;290(7):4163-77. doi: 10.1074/jbc.M114.626929. Epub 2014 Dec 22.

PMID:
25533466
10.

Role of Cdk1 in the p53-independent abrogation of the postmitotic checkpoint by human papillomavirus E6.

Zhang W, Liu Y, Zhao N, Chen H, Qiao L, Zhao W, Chen JJ.

J Virol. 2015 Mar;89(5):2553-62. doi: 10.1128/JVI.02269-14. Epub 2014 Dec 17.

PMID:
25520504
11.

Reversible cell cycle inhibition and premature aging features imposed by conditional expression of p16Ink4a.

Boquoi A, Arora S, Chen T, Litwin S, Koh J, Enders GH.

Aging Cell. 2015 Feb;14(1):139-47. doi: 10.1111/acel.12279. Epub 2014 Dec 6.

12.

Pin1-mediated Sp1 phosphorylation by CDK1 increases Sp1 stability and decreases its DNA-binding activity during mitosis.

Yang HC, Chuang JY, Jeng WY, Liu CI, Wang AH, Lu PJ, Chang WC, Hung JJ.

Nucleic Acids Res. 2014 Dec 16;42(22):13573-87. doi: 10.1093/nar/gku1145. Epub 2014 Nov 14.

13.

In silico design and biological evaluation of a dual specificity kinase inhibitor targeting cell cycle progression and angiogenesis.

Latham AM, Kankanala J, Fearnley GW, Gage MC, Kearney MT, Homer-Vanniasinkam S, Wheatcroft SB, Fishwick CW, Ponnambalam S.

PLoS One. 2014 Nov 13;9(11):e110997. doi: 10.1371/journal.pone.0110997. eCollection 2014.

14.

CDK1 plays an important role in the maintenance of pluripotency and genomic stability in human pluripotent stem cells.

Neganova I, Tilgner K, Buskin A, Paraskevopoulou I, Atkinson SP, Peberdy D, Passos JF, Lako M.

Cell Death Dis. 2014 Nov 6;5:e1508. doi: 10.1038/cddis.2014.464.

15.

Polyisoprenylated methylated protein methyl esterase as a putative drug target for androgen-insensitive prostate cancer.

Poku RA, Amissah F, Duverna R, Aguilar BJ, Kiros GE, Lamango NS.

Ecancermedicalscience. 2014 Aug 28;8:459. doi: 10.3332/ecancer.2014.459. eCollection 2014.

16.

Cyclin-dependent kinases.

Malumbres M.

Genome Biol. 2014;15(6):122. Review.

PMID:
25180339
17.

βTrCP controls the lysosome-mediated degradation of CDK1, whose accumulation correlates with tumor malignancy.

Herrero-Ruiz J, Mora-Santos M, Giráldez S, Sáez C, Japón MA, Tortolero M, Romero F.

Oncotarget. 2014 Sep 15;5(17):7563-74.

18.

Nuclear removal during terminal lens fiber cell differentiation requires CDK1 activity: appropriating mitosis-related nuclear disassembly.

Chaffee BR, Shang F, Chang ML, Clement TM, Eddy EM, Wagner BD, Nakahara M, Nagata S, Robinson ML, Taylor A.

Development. 2014 Sep;141(17):3388-98. doi: 10.1242/dev.106005.

19.

Evaluation of correlation of cell cycle proteins and Ki-67 interaction in paranasal sinus inverted papilloma prognosis and squamous cell carcinoma transformation.

Tsou YA, Huang HJ, Wang TC, Tai CJ, Chen CM, Chen CY.

Biomed Res Int. 2014;2014:634945. doi: 10.1155/2014/634945. Epub 2014 Jun 12.

20.

Phosphorylation status of thymidine kinase 1 following antiproliferative drug treatment mediates 3'-deoxy-3'-[18F]-fluorothymidine cellular retention.

Sala R, Nguyen QD, Patel CB, Mann D, Steinke JH, Vilar R, Aboagye EO.

PLoS One. 2014 Jul 8;9(7):e101366. doi: 10.1371/journal.pone.0101366. eCollection 2014.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk